Pacanalotamab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A short half-life bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of pacanalotamab, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.

**Synonyms:** - AMG 420 - AMG-420 - AMG420 - Anti-BCMA x Anti-CD3 BiTE AMG 420 - Anti-BCMA/CD3 BiTE Antibody AMG 420 - BCMA/CD3-directed Bispecific T-cell Engager Antibody AMG 420 - BI 836909 - BI-836909 - BI836909 - BiTE Antibody AMG 420 - Bispecific T-cell Engager Antibody AMG 420 - PACANALOTAMAB